Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade

BackgroundHigh-grade sarcomas are a heterogeneous group of aggressive tumors arising in bone and soft tissues. After relapse, treatment options are limited. The multi-targeted receptor tyrosine kinase inhibitors (TKIs) sunitinib and inhibitor of PD-1 (anti-PD-1) nivolumab have shown antitumor activi...

Full description

Bibliographic Details
Main Authors: Darina Ocadlikova, Mariangela Lecciso, Javier Martin Broto, Katia Scotlandi, Michele Cavo, Antonio Curti, Emanuela Palmerini
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
osteosarcoma
synovial sarcoma
tyrosine kinase inhibitor (TKI)
nivolumab (PubChem SID: 178103907)
sunitinib (PubChem CID: 5329102)
immunomodulation
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.577766/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.577766/full

Similar Items